Skip to content

Released Mar 6, 2018, before the open

10-K filed Mar 6, 2018, 65 days after period end · 0001144204-18-013053

Q4 2017 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$4.31Mderived+106.9% vs Q4 2016−42.8% vs Q3 2017
Net Income-$13.31MderivedN/M vs Q4 2016N/M vs Q3 2017
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$915,000+609.3%
Operating Incomederived-$9,582,000N/M
Operating Cash Flowderived$17,590,000N/M
Free Cash Flowderived$17,300,000N/M
Margins · derived
Gross margin21.3%+15.1 pt vs Q4 2016
Operating margin-222.6%+196.5 pt vs Q4 2016
Net margin-309.1%−183.0 pt vs Q4 2016

What the release said

The release

Same quarter

MetricQ4 2017derived from reported figuresQ4 2016derived from reported figuresQ4 2015derived from reported figuresQ4 2014derived from reported figures
Revenue$4.31M$2.08M$0.00—
Net Income-$13.31M-$2.62M$72.90M-$8.47M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR